[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse TNFAIP3

Summary
SymbolTNFAIP3
Nametumor necrosis factor, alpha-induced protein 3
Aliases OTUD7C; TNFA1P2; OTU domain-containing protein 7C; TNF alpha-induced protein 3; putative DNA-binding protein ......
Chromosomal Location6q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Nucleus. Lysosome.; SUBCELLULAR LOCATION: A20p50: Cytoplasm.
Domain PF02338 OTU-like cysteine protease
PF01754 A20-like zinc finger
Function

Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on 'Lys-63'-linked polyubiquitin. Upon T-cell receptor (TCR)-mediated T-cell activation, deubiquitinates 'Lys-63'-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate 'Lys-11'-, 'Lys-48'- and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. Required for LPS-induced production of proinflammatory cytokines and IFN beta in LPS-tolerized macrophages.

> Gene Ontology
 
Biological Process GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0000209 protein polyubiquitination
GO:0000302 response to reactive oxygen species
GO:0001525 angiogenesis
GO:0001776 leukocyte homeostasis
GO:0001782 B cell homeostasis
GO:0001818 negative regulation of cytokine production
GO:0001889 liver development
GO:0001894 tissue homeostasis
GO:0001922 B-1 B cell homeostasis
GO:0001933 negative regulation of protein phosphorylation
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0002158 osteoclast proliferation
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002260 lymphocyte homeostasis
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002467 germinal center formation
GO:0002507 tolerance induction
GO:0002544 chronic inflammatory response
GO:0002634 regulation of germinal center formation
GO:0002676 regulation of chronic inflammatory response
GO:0002677 negative regulation of chronic inflammatory response
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002753 cytoplasmic pattern recognition receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002819 regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002831 regulation of response to biotic stimulus
GO:0002832 negative regulation of response to biotic stimulus
GO:0006469 negative regulation of protein kinase activity
GO:0006979 response to oxidative stress
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors
GO:0009615 response to virus
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010035 response to inorganic substance
GO:0010803 regulation of tumor necrosis factor-mediated signaling pathway
GO:0016579 protein deubiquitination
GO:0022612 gland morphogenesis
GO:0023035 CD40 signaling pathway
GO:0030522 intracellular receptor signaling pathway
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0031348 negative regulation of defense response
GO:0031349 positive regulation of defense response
GO:0031396 regulation of protein ubiquitination
GO:0031397 negative regulation of protein ubiquitination
GO:0031663 lipopolysaccharide-mediated signaling pathway
GO:0031664 regulation of lipopolysaccharide-mediated signaling pathway
GO:0031665 negative regulation of lipopolysaccharide-mediated signaling pathway
GO:0032088 negative regulation of NF-kappaB transcription factor activity
GO:0032102 negative regulation of response to external stimulus
GO:0032479 regulation of type I interferon production
GO:0032480 negative regulation of type I interferon production
GO:0032495 response to muramyl dipeptide
GO:0032496 response to lipopolysaccharide
GO:0032606 type I interferon production
GO:0032611 interleukin-1 beta production
GO:0032612 interleukin-1 production
GO:0032623 interleukin-2 production
GO:0032635 interleukin-6 production
GO:0032640 tumor necrosis factor production
GO:0032651 regulation of interleukin-1 beta production
GO:0032652 regulation of interleukin-1 production
GO:0032663 regulation of interleukin-2 production
GO:0032675 regulation of interleukin-6 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032691 negative regulation of interleukin-1 beta production
GO:0032692 negative regulation of interleukin-1 production
GO:0032703 negative regulation of interleukin-2 production
GO:0032715 negative regulation of interleukin-6 production
GO:0032720 negative regulation of tumor necrosis factor production
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0033002 muscle cell proliferation
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0033673 negative regulation of kinase activity
GO:0034103 regulation of tissue remodeling
GO:0034104 negative regulation of tissue remodeling
GO:0034121 regulation of toll-like receptor signaling pathway
GO:0034122 negative regulation of toll-like receptor signaling pathway
GO:0034134 toll-like receptor 2 signaling pathway
GO:0034135 regulation of toll-like receptor 2 signaling pathway
GO:0034136 negative regulation of toll-like receptor 2 signaling pathway
GO:0034138 toll-like receptor 3 signaling pathway
GO:0034139 regulation of toll-like receptor 3 signaling pathway
GO:0034140 negative regulation of toll-like receptor 3 signaling pathway
GO:0034142 toll-like receptor 4 signaling pathway
GO:0034143 regulation of toll-like receptor 4 signaling pathway
GO:0034144 negative regulation of toll-like receptor 4 signaling pathway
GO:0034146 toll-like receptor 5 signaling pathway
GO:0034147 regulation of toll-like receptor 5 signaling pathway
GO:0034148 negative regulation of toll-like receptor 5 signaling pathway
GO:0034599 cellular response to oxidative stress
GO:0034612 response to tumor necrosis factor
GO:0034614 cellular response to reactive oxygen species
GO:0035871 protein K11-linked deubiquitination
GO:0035872 nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway
GO:0042113 B cell activation
GO:0042176 regulation of protein catabolic process
GO:0042326 negative regulation of phosphorylation
GO:0042542 response to hydrogen peroxide
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043124 negative regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045124 regulation of bone resorption
GO:0045453 bone resorption
GO:0045732 positive regulation of protein catabolic process
GO:0045736 negative regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0045765 regulation of angiogenesis
GO:0045779 negative regulation of bone resorption
GO:0045786 negative regulation of cell cycle
GO:0045824 negative regulation of innate immune response
GO:0046849 bone remodeling
GO:0046850 regulation of bone remodeling
GO:0046851 negative regulation of bone remodeling
GO:0048514 blood vessel morphogenesis
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048662 negative regulation of smooth muscle cell proliferation
GO:0048732 gland development
GO:0048771 tissue remodeling
GO:0048871 multicellular organismal homeostasis
GO:0048872 homeostasis of number of cells
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050688 regulation of defense response to virus
GO:0050691 regulation of defense response to virus by host
GO:0050727 regulation of inflammatory response
GO:0050728 negative regulation of inflammatory response
GO:0050777 negative regulation of immune response
GO:0050792 regulation of viral process
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050869 negative regulation of B cell activation
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051259 protein oligomerization
GO:0051348 negative regulation of transferase activity
GO:0051607 defense response to virus
GO:0060055 angiogenesis involved in wound healing
GO:0060249 anatomical structure homeostasis
GO:0060759 regulation of response to cytokine stimulus
GO:0061008 hepaticobiliary system development
GO:0061041 regulation of wound healing
GO:0061042 vascular wound healing
GO:0061043 regulation of vascular wound healing
GO:0070301 cellular response to hydrogen peroxide
GO:0070423 nucleotide-binding oligomerization domain containing signaling pathway
GO:0070424 regulation of nucleotide-binding oligomerization domain containing signaling pathway
GO:0070425 negative regulation of nucleotide-binding oligomerization domain containing signaling pathway
GO:0070427 nucleotide-binding oligomerization domain containing 1 signaling pathway
GO:0070428 regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway
GO:0070429 negative regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway
GO:0070431 nucleotide-binding oligomerization domain containing 2 signaling pathway
GO:0070432 regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway
GO:0070433 negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway
GO:0070536 protein K63-linked deubiquitination
GO:0070646 protein modification by small protein removal
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070664 negative regulation of leukocyte proliferation
GO:0070936 protein K48-linked ubiquitination
GO:0071108 protein K48-linked deubiquitination
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071356 cellular response to tumor necrosis factor
GO:0071396 cellular response to lipid
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:0071947 protein deubiquitination involved in ubiquitin-dependent protein catabolic process
GO:0072573 tolerance induction to lipopolysaccharide
GO:0072574 hepatocyte proliferation
GO:0072575 epithelial cell proliferation involved in liver morphogenesis
GO:0072576 liver morphogenesis
GO:0072577 endothelial cell apoptotic process
GO:0072665 protein localization to vacuole
GO:0072666 establishment of protein localization to vacuole
GO:0090289 regulation of osteoclast proliferation
GO:0090291 negative regulation of osteoclast proliferation
GO:0097191 extrinsic apoptotic signaling pathway
GO:0098542 defense response to other organism
GO:1901342 regulation of vasculature development
GO:1901652 response to peptide
GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1902532 negative regulation of intracellular signal transduction
GO:1903034 regulation of response to wounding
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903321 negative regulation of protein modification by small protein conjugation or removal
GO:1903362 regulation of cellular protein catabolic process
GO:1903364 positive regulation of cellular protein catabolic process
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903556 negative regulation of tumor necrosis factor superfamily cytokine production
GO:1904019 epithelial cell apoptotic process
GO:1904029 regulation of cyclin-dependent protein kinase activity
GO:1904030 negative regulation of cyclin-dependent protein kinase activity
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904036 negative regulation of epithelial cell apoptotic process
GO:2000027 regulation of organ morphogenesis
GO:2000345 regulation of hepatocyte proliferation
GO:2000347 positive regulation of hepatocyte proliferation
GO:2000348 regulation of CD40 signaling pathway
GO:2000349 negative regulation of CD40 signaling pathway
GO:2000351 regulation of endothelial cell apoptotic process
GO:2000352 negative regulation of endothelial cell apoptotic process
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
Molecular Function GO:0002020 protease binding
GO:0004842 ubiquitin-protein transferase activity
GO:0004843 thiol-dependent ubiquitin-specific protease activity
GO:0008234 cysteine-type peptidase activity
GO:0016874 ligase activity
GO:0019783 ubiquitin-like protein-specific protease activity
GO:0019787 ubiquitin-like protein transferase activity
GO:0031593 polyubiquitin binding
GO:0032182 ubiquitin-like protein binding
GO:0036459 thiol-dependent ubiquitinyl hydrolase activity
GO:0043130 ubiquitin binding
GO:0043621 protein self-association
GO:0070530 K63-linked polyubiquitin binding
GO:0101005 ubiquitinyl hydrolase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04064 NF-kappa B signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04668 TNF signaling pathway
Reactome R-HSA-73887: Death Receptor Signalling
R-HSA-5688426: Deubiquitination
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-392499: Metabolism of proteins
R-HSA-168638: NOD1/2 Signaling Pathway
R-HSA-936440: Negative regulators of RIG-I/MDA5 signaling
R-HSA-168643: Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
R-HSA-5689896: Ovarian tumor domain proteases
R-HSA-597592: Post-translational protein modification
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
R-HSA-5357905: Regulation of TNFR1 signaling
R-HSA-162582: Signal Transduction
R-HSA-75893: TNF signaling
R-HSA-5357956: TNFR1-induced NFkappaB signaling pathway
R-HSA-5357786: TNFR1-induced proapoptotic signaling
Summary
SymbolTNFAIP3
Nametumor necrosis factor, alpha-induced protein 3
Aliases OTUD7C; TNFA1P2; OTU domain-containing protein 7C; TNF alpha-induced protein 3; putative DNA-binding protein ......
Chromosomal Location6q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TNFAIP3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TNFAIP3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25024217melanomaInhibit immunityThe tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells.
Summary
SymbolTNFAIP3
Nametumor necrosis factor, alpha-induced protein 3
Aliases OTUD7C; TNFA1P2; OTU domain-containing protein 7C; TNF alpha-induced protein 3; putative DNA-binding protein ......
Chromosomal Location6q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TNFAIP3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTNFAIP3
Nametumor necrosis factor, alpha-induced protein 3
Aliases OTUD7C; TNFA1P2; OTU domain-containing protein 7C; TNF alpha-induced protein 3; putative DNA-binding protein ......
Chromosomal Location6q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TNFAIP3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4240.312
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.0890.507
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0580.961
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.480.465
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.2570.615
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5110.881
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6690.184
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8410.578
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5410.737
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8210.444
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4840.36
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2580.15
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TNFAIP3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTNFAIP3
Nametumor necrosis factor, alpha-induced protein 3
Aliases OTUD7C; TNFA1P2; OTU domain-containing protein 7C; TNF alpha-induced protein 3; putative DNA-binding protein ......
Chromosomal Location6q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNFAIP3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTNFAIP3
Nametumor necrosis factor, alpha-induced protein 3
Aliases OTUD7C; TNFA1P2; OTU domain-containing protein 7C; TNF alpha-induced protein 3; putative DNA-binding protein ......
Chromosomal Location6q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNFAIP3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNFAIP3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTNFAIP3
Nametumor necrosis factor, alpha-induced protein 3
Aliases OTUD7C; TNFA1P2; OTU domain-containing protein 7C; TNF alpha-induced protein 3; putative DNA-binding protein ......
Chromosomal Location6q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNFAIP3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTNFAIP3
Nametumor necrosis factor, alpha-induced protein 3
Aliases OTUD7C; TNFA1P2; OTU domain-containing protein 7C; TNF alpha-induced protein 3; putative DNA-binding protein ......
Chromosomal Location6q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TNFAIP3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTNFAIP3
Nametumor necrosis factor, alpha-induced protein 3
Aliases OTUD7C; TNFA1P2; OTU domain-containing protein 7C; TNF alpha-induced protein 3; putative DNA-binding protein ......
Chromosomal Location6q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TNFAIP3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTNFAIP3
Nametumor necrosis factor, alpha-induced protein 3
Aliases OTUD7C; TNFA1P2; OTU domain-containing protein 7C; TNF alpha-induced protein 3; putative DNA-binding protein ......
Chromosomal Location6q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TNFAIP3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.